Last reviewed 2026-04-22 · How we verify

Brinzolamide/brimonidine ophthalmic suspension

Brinzolamide/brimonidine ophthalmic suspension is a Carbonic anhydrase inhibitor / Alpha-2 adrenergic agonist combination Small molecule drug developed by Padagis LLC. It is currently in Phase 3 development for Open-angle glaucoma, Ocular hypertension.

Brinzolamide reduces aqueous humor production via carbonic anhydrase inhibition, while brimonidine decreases aqueous humor production and increases uveoscleral outflow via alpha-2 adrenergic receptor agonism, together lowering intraocular pressure.

Brinzolamide reduces aqueous humor production via carbonic anhydrase inhibition, while brimonidine decreases aqueous humor production and increases uveoscleral outflow via alpha-2 adrenergic receptor agonism, together lowering intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.

At a glance

Mechanism of action

Brinzolamide is a topical carbonic anhydrase inhibitor that decreases aqueous humor secretion in the ciliary body. Brimonidine is an alpha-2 adrenergic agonist that reduces aqueous humor production and enhances drainage through the uveoscleral pathway. The combination provides complementary mechanisms to reduce intraocular pressure in glaucoma and ocular hypertension.

Approved indications

• Open-angle glaucoma
• Ocular hypertension

Common side effects

• Ocular hyperemia
• Blurred vision
• Ocular discomfort
• Taste perversion
• Allergic conjunctivitis

Key clinical trials

• Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost (PHASE4)
• To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes (PHASE3)
• Brinzolamide-brimonidine Fixed Combination for Preventing IOP Elevation After Intravitreal Anti-VEGF Injections (NA)
• Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma (PHASE4)
• Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV® (PHASE4)
• SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA) (PHASE4)
• Efficacy and Safety of Brinzolamide/Brimonidine Fixed Combination BID Compared to Brinzolamide BID Plus Brimonidine BID in Subjects With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT) (PHASE3)
• 24-hr Intraocular Pressure Control With SIMBRINZA ® (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Brinzolamide/brimonidine ophthalmic suspension CI brief — competitive landscape report
• Brinzolamide/brimonidine ophthalmic suspension updates RSS · CI watch RSS
• Padagis LLC portfolio CI

Frequently asked questions about Brinzolamide/brimonidine ophthalmic suspension

Related

• Drug class: All Carbonic anhydrase inhibitor / Alpha-2 adrenergic agonist combination drugs
• Target: All drugs targeting Carbonic anhydrase II; Alpha-2 adrenergic receptor
• Manufacturer: Padagis LLC — full pipeline
• Therapeutic area: All drugs in Ophthalmology
• Indication: Drugs for Open-angle glaucoma
• Indication: Drugs for Ocular hypertension
• Compare: Brinzolamide/brimonidine ophthalmic suspension vs similar drugs
• Pricing: Brinzolamide/brimonidine ophthalmic suspension cost, discount & access